Modified donor immune cells tested in acute leukemia returning after stem cell transplant
Tests modified donor immune cells in people with acute leukemia that returned after transplant.
Key facts
- Who runs it
- Fred Hutchinson Cancer Center
- Where
- Seattle, United StatesSee the site
- Trial code
- Registry title
- HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 24 people, planned
- Started
- 23 Feb 2018
- Expected to end
- 16 Jul 2028
- Type of study
- Interventional
- Treatments tested
- CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
- Bone Marrow Aspiration
- Biospecimen Collection
- Record updated
- 18 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and adults whose acute leukemia or related blood cancer is back or persists after a donor stem cell transplant. They must carry specific tissue markers.
- Age
- 0 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Acute leukemia, blast-phase chronic myeloid leukemia, myelodysplastic syndrome, CMML or JMML that came back, did not respond, or has rising minimal residual disease after a donor stem cell transplant (HCT).
- Earlier treatment
- Must have had or be having a donor stem cell transplant (allogeneic HCT). Other treatments for relapse or MRD are allowed.
- Biomarker or test result
- HLA-A*0201 positive and HA-1(H) genotype (RS_1801284: A/G or A/A). The transplant donor must be HLA-A*0201 positive and HA-1(H) negative (G/G), or HLA-A*0201 negative.
Main reasons for not taking part
- Medical or psychological conditions that make cell therapy unsuitable, as judged by the principal investigator
- Fertile people unwilling to use contraception during treatment and for 12 months after
- Life expectancy under 3 months from a disease other than leukemia
- Ongoing grade IV acute GVHD or severe chronic GVHD after the latest transplant, with a possible exception at the investigator's discretion
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Subject age 0-80 years at the time of enrollment
- Subject must express HLA-A*0201
- Subject must have the HA-1(H) genotype (RS_1801284: A/G, A/A)
- Subject must have an adult donor for HCT who is adequately HLA matched by institutional standards (includes HLA-matched related or unrelated donors, and HLA-mismatched family donors, including haploidentical donors) and is either:; HLA-A*0201 positive and HA-1(H) negative (RS_1801284: G/G) or; HLA-A*0201 negative
- Subjects who are currently undergoing or who previously underwent allogeneic HCT for; Acute myeloid leukemia (AML) of any subtype; Acute lymphoid leukemia (ALL) of any subtype; Mixed phenotype/undifferentiated/any other type of acute leukemia, including blastic plasmacytoid dendritic cell neoplasm; Chronic myeloid leukemia with a history of blast crisis and:; With relapse or refractory disease (>= 5% marrow blasts, or circulating blasts) at any time after HCT; With persistent rising minimal residual disease (defined as detectable disease by morphology, flow cytometry, molecular or cytogenetic testing but < 5% marrow blasts by morphology, no circulating blasts on >= 2 of two consecutive tests), refractory or ineligible for treatment with tyrosine kinase inhibitors at any time after HCT; Myelodysplastic syndrome (MDS) of any subtype; Chronic myelomonocytic leukemia (CMML); Juvenile myelomonocytic leukemia (JMML)
- Subjects must be able to understand and be willing to give informed consent; decision-impaired adults may consent with their legally authorized representative; parent or legal representative will be asked to consent for subjects younger than 18 years old
- Subjects must agree to participate in long-term follow-up for up to 15 years if they are enrolled in the study and receive T cell infusion
- Subjects who have relapsed or have MRD after HCT may receive other agents for treatment of disease and remain eligible for the protocol
- A specific performance status score is not required for enrolling on the protocol; a delay in infusion of the HA-1 TCR T cells may be required for subjects with low performance status; DONOR SELECTION INCLUSION
- Donor age >= 18 years
- Donors must be able to give informed consent
Who cannot take part
- Subjects who have ongoing grade IV acute GVHD or severe chronic GVHD following most recent transplant. Exception: the principal investigator (PI) may make an exception on a case-by-case basis to include such a subject if there is doubt surrounding the GVHD diagnosis and/or sustained significant improvement in GVHD severity
- Medical or psychological conditions that would make the subject unsuitable candidate for cell therapy at the discretion of the principal investigator (PI)
- Subjects with a life expectancy of < 3 months of enrollment from coexisting disease other than leukemia
- Donors who are human immunodeficiency virus (HIV)-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2 seropositive or with active hepatitis B or hepatitis C virus infection
- Fertile subjects unwilling to use contraception during and for 12 months after treatment
- The presence of organ toxicities will not necessarily exclude subjects from enrolling on the protocol at the discretion of the PI; however, a delay in the infusion of HA-1 TCR T cells may be required; DONOR SELECTION EXCLUSION
- Unrelated donor residing outside of the United States of America (USA) unless the donor screening, testing and leukapheresis occur at an National Marrow Donor Program (NMDP)-affiliated and qualified donor center and are facilitated by the NMDP
Where in United States
- Fred Hutch/University of Washington Cancer ConsortiumSeattle, United StatesContact: FHCC Immunotherapy IntakeTaking people
About the trial
What the trial wants to find out
This phase I trial studies the side effects and best dose of CD4+ and CD8+ HA-1 T cell receptor (TCR) (HA-1 T TCR) T cells in treating patients with acute leukemia that persists, has come back (recurrent) or does not respond to treatment (refractory) following donor stem cell transplant. T cell receptor is a special protein on T cells that helps them recognize proteins on other cells including leukemia. HA-1 is a protein that is present on the surface of some peoples' blood cells, including leukemia. HA-1 T cell immunotherapy enables genes to be added to the donor cells to make them recognize HA-1 markers on leukemia cells.
The group in the trial
- Treatment (CD4+ and CD8+ HA-1 TCR T cells)Treatment being tested
Patients receive lymphodepleting chemotherapy (e.g., fludarabine and cyclophosphamide or debulking regimens as specified in the protocol) ending 2-14 days prior to HA-1 TCR T cell administration. Patients then receive CD4+ and CD8+ HA-1 TCR T cells IV.
Treatment: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, and Biospecimen Collection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Phase I Study of Adoptive Immunotherapy With CD8+ and CD4+ Memory T Cells Transduced to Express an HA-1-Specific T Cell Receptor (TCR) for Children and Adults With Recurrent Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation (HCT)
- Plain-language title
- Modified donor immune cells tested in acute leukemia returning after stem cell transplantGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 18 May 2026